Metraipolis › archive › dc_6d3e2adfec22

Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease — Europe PMC PMID:42549165

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42549165
DOI
10.3389/fphar.2026.1847907
License (as archived)
solo-consultazione
Archived
2026-10-18T03:57:39.064Z
SHA-256 of the archived text
a6b0122ab831bf18ce48e1d662fff15fc32ee4c358550360e3c3376253f8a900
Stable URL of this page
https://metraipolis.com/documento/dc_6d3e2adfec22

How to cite

Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease — Europe PMC PMID:42549165 — Europe PMC (en), https://europepmc.org/article/MED/42549165 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6d3e2adfec22 (Metraipolis archive dc_6d3e2adfec22, sha256 a6b0122ab831bf18ce48e1d662fff15fc32ee4c358550360e3c3376253f8a900)
BibTeX
@misc{dc6d3e2adfec22,
  title = {Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease — Europe PMC PMID:42549165},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42549165},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6d3e2adfec22; sha256 a6b0122ab831bf18ce48e1d662fff15fc32ee4c358550360e3c3376253f8a900},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42549165. Agents can read the archived copy with the MCP tool read_document.